Recently, “TCR1672”, a second-generation, highly selective P2X3 receptor antagonist self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration of China to commence clinical trial for refractory chronic cough (RCC) in China.
P2X3 receptor is a ligand-gated ion channel in the purine receptors family. Studies have shown that over-activation of P2X3 receptor is associated with hyper-sensitization of sensory neurons. Excessive, persistent and frequent coughs can be caused by injury or infection-induced hypersensitivity of airway and lung neurons. TCR1672 blocks the calcium ion influx from P2X3 receptor initiated by adenosine triphosphate (ATP), thereby exerting its specific inhibitory action to achieve therapeutic effect. Preclinical studies have shown that TCR1672 not only significantly reduces the frequency of coughing in patients with refractory chronic cough, but also has a significant effect on pain relief in patients with endometriosis. The Group will continue to explore the use of TCR1672 in neuropathic pain and cancer pain.